NYSE : ENOV
Enovis Corporation — Key statistics
Healthcare · Medical Devices · United States
Last price 19.91 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.15B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.15B |
| Enterprise Value | 2.50B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 57.67M |
| Shares Outstanding | 57.67M |
| Shares Change (YoY) | +1.67% |
| Shares Change (QoQ) | +0.50% |
| Owned by Insiders (%) | 1.72% |
| Owned by Institutions (%) | 111.32% |
| Float | 52.76M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 5.60 |
| PS Ratio | 0.50 |
| Forward PS | 0.48 |
| PB Ratio | 0.78 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 18.04 |
| P/OCF Ratio | 4.25 |
| PEG Ratio | 0.82 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.09 |
| EV / EBITDA | 6.60 |
| EV / EBIT | 29.82 |
| EV / FCF | 39.35 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.98 |
| Quick Ratio | 0.74 |
| Debt / Equity | 0.93 |
| Debt / EBITDA | 3.40 |
| Debt / FCF | 21.51 |
| Interest Coverage | 1.07 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -54.14% |
| Return on Assets (ROA) | 1.19% |
| Return on Invested Capital (ROIC) | 2.95% |
| Return on Capital Employed (ROCE) | 2.66% |
| Weighted Average Cost of Capital (WACC) | 8.13% |
| Revenue Per Employee | $294,361 |
| Profits Per Employee | -$141,206 |
| Employee Count | 7,802 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 1.44 |
Taxes
| Measure | Value |
|---|
| Income Tax | 30.81M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.48 |
| 52-Week Price Change | -37.76% |
| 50-Day Moving Average | 20.01 |
| 200-Day Moving Average | 23.07 |
| Relative Strength Index (RSI) | 48.28 |
| Average Volume (20 Days) | 1,342,033 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 11.70M |
| Short Previous Month | 9.48M |
| Short % of Shares Out | 20.29% |
| Short % of Float | 22.18% |
| Short Ratio (days to cover) | 7.14 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 2.30B |
| Gross Profit | 1.41B |
| Operating Income | 84.01M |
| Pretax Income | -1.07B |
| Net Income | -1.10B |
| EBITDA | 379.78M |
| EBIT | 84.01M |
| Loss Per Share | -$19.22 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 12.56M |
| Total Debt | 1.37B |
| Net Cash | -1.36B |
| Net Cash Per Share | -$23.52 |
| Equity (Book Value) | 1.48B |
| Book Value Per Share | 25.61 |
| Working Capital | 602.64M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 270.10M |
| Capital Expenditures | -206.44M |
| Depreciation & Amortization | 295.77M |
| Net Borrowing | -113.94M |
| Free Cash Flow | 63.66M |
| FCF Per Share | $1.10 |
Margins
| Measure | Value |
|---|
| Gross Margin | 61.32% |
| Operating Margin | 3.66% |
| Pretax Margin | -46.52% |
| Profit Margin | -47.97% |
| EBITDA Margin | 16.54% |
| EBIT Margin | 3.66% |
| FCF Margin | 2.77% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.67% |
| Shareholder Yield | -1.67% |
| Earnings Yield | -96.54% |
| FCF Yield | 5.54% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $36.08 |
| Price Target Difference | 81.22% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 4.55% |
| EPS Growth Forecast (3Y) | 5.32% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Apr 5, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:3 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.73 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |